Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Mallinckrodt Medical/Sandoz Pharma

  • News

Executive Summary

Enter agreement to develop and radiolabel molecules for radiodiagnostics and radiotherapeutic products. The deal, announced Dec. 16 by Mallinckrodt parent IMCERA (Northbrook, Ill.) and Sandoz Pharma Ltd. (Basel) gives Mallinckrodt exclusive worldwide rights to diagnostic products generated by the collaboration; Sandoz will receive exclusive rights to any therapeutic products commercialized. Financial terms were not disclosed. The contract, initially for five years with possible extensions, grows out of a March 1991 agreement for Mallinckrodt to develop and market an Indium-111 radiolabeled cancer imaging agent (OctreoScan-111) based on Sandoz' Sandostatin (octreotide). Mallinckrodt filed an NDA for OctreoScan-111 for abdominal tumor imaging on Oct. 22 ("The Pink Sheet" Oct. 26, T&G- 1).

Table

View full table

Tags:
Latest Headlines

Medicare Negotiation Second Cycle Draft Guidance Offers Options For ‘Effectuating’ Prices

Medicare Negotiation Timeline For Prices To Be Implemented In 2027

What’s The Key To Successful R&D With Artificial Intelligence? ‘Bilingual’ Scientists

Pink Sheet Podcast: US FDA Adcomm Reform, Clinical Trial Modeling Boost, AI For Drug Review

See All
UsernamePublicRestriction

Register

PS021935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By